CD274 and head and neck squamous cell carcinoma: Emerging evidence has demonstrated that the immune checkpoint targeting agent (such as Pembrolizumab) either alone or combined with chemotherapy significantly prolongs OS of the recurrent/metastatic HNSCC with a CPS (the PD-L1 combined positive score) of ≥20, as compared to cetuximab with chemotherapy (45, 46).